#aznstock — Public Fediverse posts

AstraZeneca Gets FDA Priority Review for IMFINZI Combo

AstraZeneca received U.S. FDA Priority Review for IMFINZI plus enfortumab vedotin as a potential treatment for certain muscle-invasive…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AZNstock #bladdercancertreatment #CancerResearch #durvalumab #enfortumabvedotin #FDAPriorityReview #Imfinzi #immunotherapy #nasdaq-azn #OncologyDrugs #pharmaceuticalstocks #VOLGAtrial
https://www.europesays.com/britain/131497/

https://www.europesays.com/britain/131497/ AstraZeneca Gets FDA Priority Review for IMFINZI Combo #AstraZeneca #AZNStock #BladderCancerTreatment #CancerResearch #durvalumab #EnfortumabVedotin #FDAPriorityReview #Imfinzi #immunotherapy #NasdaqAzn #OncologyDrugs #PharmaceuticalStocks #VOLGATrial

Can AstraZeneca’s Broad Pipeline Offset Recent Setbacks?

AstraZeneca’s AZN stock has taken a beating recently, with the company facing several pipeline setbacks in the past…
#EuropeSays #Britain #Europe #EU #AstraZeneca #advancedbreastcancer #ATTR-CM #AZNstock #PCSK9inhibitor #PhaseIII #ZacksInvestmentResearch
https://www.europesays.com/britain/127192/

https://www.europesays.com/britain/127192/ Can AstraZeneca’s Broad Pipeline Offset Recent Setbacks? #AdvancedBreastCancer #AstraZeneca #ATTRCM #AZNStock #PCSK9Inhibitor #PhaseIII #ZacksInvestmentResearch

FDA Grants Priority Review to AZN’s Filing for Rare Bone Disease Drug

AstraZeneca AZN announced that the FDA accepted its regulatory filing seeking approval for its investigational enzyme replacement therapy…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AZNstock #bonehealth #enzymereplacementtherapy #FDA #HPP #Strensiq #ZacksInvestmentResearch
https://www.europesays.com/britain/127000/

https://www.europesays.com/britain/127000/ FDA Grants Priority Review to AZN’s Filing for Rare Bone Disease Drug #AstraZeneca #AZNStock #BoneHealth #EnzymeReplacementTherapy #FDA #HPP #Strensiq #ZacksInvestmentResearch

AstraZeneca acquires ZEGFROVY rights for $600 million

AstraZeneca completed an exclusive license agreement with Dizal Pharmaceutical for global ZEGFROVY rights.The deal includes a $600 million…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AZNstock #DizalPharmaceutical #EGFRinhibitor #lungcancertreatment #nsclc #OncologyDrugs #pharmaceuticallicensing #Sunvozertinib #Zegfrovy
https://www.europesays.com/britain/115176/

https://www.europesays.com/britain/115176/ AstraZeneca acquires ZEGFROVY rights for $600 million #AstraZeneca #AZNStock #DizalPharmaceutical #EGFRInhibitor #LungCancerTreatment #nsclc #OncologyDrugs #PharmaceuticalLicensing #Sunvozertinib #Zegfrovy

BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’

Analysts largely viewed the miss as a significant blow to Ionis but not fatal for the company overall.…
#EuropeSays #Britain #Europe #EU #AstraZeneca #amyloidcardiomyopathy #ATTR-CM #AZNstock #BofASecurities #Ionis #RaymondJames
https://www.europesays.com/britain/80208/

https://www.europesays.com/britain/80208/ BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’ #AmyloidCardiomyopathy #AstraZeneca #ATTRCM #AZNStock #BofASecurities #Ionis #RaymondJames

AstraZeneca’s Stock Drops on Wainua’s Setback in ATTR-CM Study

Shares of AstraZeneca AZN fell nearly 8% in pre-market trading today after the company announced the failure of…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AlnylamPharmaceuticals #ATTR-CM #AZNstock #pre-markettrading #studyparticipants #ZacksInvestmentResearch
https://www.europesays.com/britain/80098/

https://www.europesays.com/britain/80098/ AstraZeneca’s Stock Drops on Wainua’s Setback in ATTR-CM Study #AlnylamPharmaceuticals #AstraZeneca #ATTRCM #AZNStock #PreMarketTrading #StudyParticipants #ZacksInvestmentResearch

AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?

AstraZeneca AZN stock has declined 7.4% in the past three months despite reporting strong first-quarter 2026 results. A key…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AZNstock #breAstcancer #DaiichiSankyo #ZacksInvestmentResearch
https://www.europesays.com/britain/64275/

https://www.europesays.com/britain/64275/ AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold? #AstraZeneca #AZNStock #BreAstCancer #DaiichiSankyo #ZacksInvestmentResearch